However, their trial (CHECKMATE 143) comparing nivolumab (an FDA-approved PD-1 inhibitor) to bevacizumab (a VEGF-A inhibitor) in recurrent glioblastoma demonstrated only an 8% response rate to nivolumab compared to a 23% response to bevacizumab (yet the duration of response was higher in the nivolumab arm, median 11.1 vs 5.3 months). The gene discussed is PDCD1; the disease is glioblastoma.